Biolegend, 303002, Purified anti-human CD29 Antibody, 100μg

CD29 is a 130 kD single chain type I glycoprotein also known as integrin β 1 , VLA-β chain, or gpIIa. It is broadly expressed on a majority of hematopoietic and non-hematopoietic cells, including leukocytes (although at low level on granulocytes), platelets, fibroblasts, endothelial cells, epithelial cells, and mast cells. CD29 is a member of the integrin family. It is non-covalently associated with integrin α1-α6 chains to form VLA-1 to VLA-6 molecules, respectively. Integrins, which include CD29, bind to several cell surface (e.g. VCAM-1, MadCAM-1) and extracellular matrix molecules. CD29 acts as a fibronectin receptor and is involved in a variety of cell-cell and cell-matrix interactions.
100μg
Verified Reactivity: Human
Reported Reactivity: African Green, Baboon, Cow, Cynomolgus, Dog, Horse, Rhesus
Antibody Type: Monoclonal
Host Species: Mouse
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/mL
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: FC - Quality tested ICC - Verified IHC, IP - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per 106 cells in 100 µL volume or 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: Additional reported applications (for the relevant formats) include: immunoprecipitation3, immunohistochemical staining of acetone-fixed frozen tissue sections3,5, and activation of integrin ß14,7,8. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 303010). Clone TS2/16 recognizes epitope A2.10
Application References(PubMed link indicates BioLegend citation): Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. Gutierrez-Lopez M, et al. 2003. J. Biol. Chem. 278:208. Hemler ME, et al. 1984. J. Immunol. 132:3011. (IHC, IP) Sanchez-Aparicio P, et al. 1994. J. Cell Biol. 126:271. (Activ) Frank NY, et al. 2005. Cancer Res. 65:4320. (IHC) Murga M, et al. 2005. Blood 105:1992. (FC) PubMed Porter JC and Hogg N. 1997. J. Cell Biol. 138:1437. (Activ) Conway RE, et al. 2006. Mol. Cell. Biol. 26:5310. (Activ) Wesseling J, et al. 1995. J. Cell. Biol. 129:255. (Dog Reactivity) Rubio G, et al. 2002. Cancer Immunol. Immunother. 51:130. Dong A, et al. 2015. J Biol Chem. 290:8016. PubMed Paebst F, et al. 2014. Cytometry A. 85(8):678-87. (Horse reactivity)
Product Citations: Mendt M, et al. 2018. JCI Insight. 9:1523. PubMed Ceccarelli S, et al. 2022. Front Cell Dev Biol. 10:926180. PubMed Friedman D, et al. 2021. J Cell Sci. 134:. PubMed Pilbauerova N, et al. 2021. Int J Mol Sci. 22:. PubMed Sivasubramaniyan K, et al. 2015. Glycobiology. 25: 902-917. PubMed Pillozzi S, et al. 2011. Blood. 117:902. PubMed Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed Novoseletskaya E, et al. 2020. Front Cell Dev Biol. 8:555378. PubMed Horwacik I, et al. 2017. Int J Oncol. 50:1899. PubMed Blázquez-Prunera A, et al. 2017. Stem Cell Res Ther. 10.1186/s13287-017-0552-z. PubMed Zhang X, et al. 2011. Am J Physiol Cell Physiol. 301:1017. PubMed Cho YY, et al. 2019. PLoS One. 14:e0210535. PubMed Olin A, et al. 2018. Cell. 174:1277. PubMed Eccles JD, et al. 2020. Cell Rep. 30:351. PubMed Henrick BM, et al. 2021. Cell. . PubMed Tanigawa K, et al. 2019. J Cell Physiol. 234:17280. PubMed Freeman SA, et al. 2020. Science. 367:301. PubMed Rogers MA, et al. 2022. Front Cardiovasc Med. 9:778919. PubMed Conway R, et al. 2006. Mol Cell Biol. 26:5310. PubMed Ran LJ, et al. 2018. Mol Med Rep. 18:723. PubMed Dong A, et al. 2015. J Biol Chem. 290:8016. PubMed
RRID: AB_314317 (BioLegend Cat. No. 303001) AB_314318 (BioLegend Cat. No. 303002)
Structure: Integrin, type I glycoprotein, forms VLA-1 to VLA-6 heterodimers with CD49a-f (α1-α6), also associates with CD51 (αV), and α7- α9, 130 kD
Distribution: Lymphocytes, monocytes, granulocytes (low), platelets, mast cells, fibroblasts, endothelial cells
Function: Cell-cell and cell-matrix interactions
Ligand/Receptor: VCAM-1, MAdCAM-1, ECM
Cell Type: Embryonic Stem Cells, Endothelial cells, Fibroblasts, Granulocytes, Lymphocytes, Mast cells, Mesenchymal Stem Cells, Monocytes, Platelets, Tregs
Biology Area: Cell Adhesion, Cell Biology, Immunology, Innate Immunity, Stem Cells
Molecular Family: Adhesion Molecules, CD Molecules
Antigen References: 1. Hemler M. 1990. Annu. Rev. Immunol. 8:365. 2. Hynes R. 1992. Cell 69:11.
Gene ID: 3688
UniProt: View information about CD29 on UniProt.org
Clone: TS2/16
Regulatory Status: RUO
Workshop: V A-S202
Other Names: Integrin β1 chain, VLA-β chain, gpIIa, ITGB1
Isotype: Mouse IgG1, κ